Cargando…

Impact of extra-articular spondyloarthritis manifestations and comorbidities on drug retention of a first TNF-inhibitor in ankylosing spondylitis: a population-based nationwide study

OBJECTIVES: To assess the impact of extra-articular spondyloarthritis (SpA) manifestations (anterior uveitis, psoriasis and inflammatory bowel disease (IBD)), and of comorbidities, on tumour necrosis factor alpha inhibitor (TNFi) drug retention in ankylosing spondylitis (AS). METHODS: We identified...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lindström, Ulf, Olofsson, Tor, Wedrén, Sara, Qirjazo, Ilia, Askling, Johan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2018
Materias:	Spondyloarthritis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6203098/ https://www.ncbi.nlm.nih.gov/pubmed/30402269 http://dx.doi.org/10.1136/rmdopen-2018-000762

Ejemplares similares

Biological treatment of ankylosing spondylitis: a nationwide study of treatment trajectories on a patient level in clinical practice
por: Lindström, Ulf, et al.
Publicado: (2019)

Predictors of extra-articular manifestations in axial spondyloarthritis and their influence on TNF-inhibitor prescribing patterns: results from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis
por: Derakhshan, Mohammad H, et al.
Publicado: (2020)

Anterior uveitis in patients with spondyloarthritis treated with secukinumab or tumour necrosis factor inhibitors in routine care: does the choice of biological therapy matter?
por: Lindström, Ulf, et al.
Publicado: (2021)

Association of childhood infections and perinatal factors with ankylosing spondylitis: a Swedish nationwide case–control and sibling study
por: Morin, Matilda, et al.
Publicado: (2023)

Comorbidity management in spondyloarthritis
por: López-Medina, Clementina, et al.
Publicado: (2020)

Predictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systematic review and meta-analysis
por: Maneiro, Jose Ramon, et al.
Publicado: (2015)

Does body mass index (BMI) influence the Ankylosing Spondylitis Disease Activity Score in axial spondyloarthritis?: Data from the SPACE cohort
por: Rubio Vargas, Roxana, et al.
Publicado: (2016)

Sick leave and its predictors in ankylosing spondylitis: long-term results from the Outcome in Ankylosing Spondylitis International Study
por: Webers, Casper, et al.
Publicado: (2018)

Do patients with ankylosing spondylitis adapt to their disease? Evidence from a ‘then-test’ in patients treated with TNF inhibitors
por: Essers, Ivette, et al.
Publicado: (2015)

Risk factors for progression of juvenile-onset non-radiographic axial spondyloarthritis to juvenile-onset ankylosing spondylitis: a nested case–control study
por: Li, Hao-Guang, et al.
Publicado: (2021)

Occurrence and relative risks for non-vertebral fractures in patients with ankylosing spondylitis compared with the general population: a register-based study from Sweden
por: Bengtsson, Karin, et al.
Publicado: (2023)

Impact of Comorbidity on Physical Function in Patients With Ankylosing Spondylitis and Psoriatic Arthritis Attending Rheumatology Clinics: Results From a Cross‐Sectional Study
por: Fernández‐Carballido, Cristina, et al.
Publicado: (2020)

Polygenic Risk Scores have high diagnostic capacity in ankylosing spondylitis
por: Li, Zhixiu, et al.
Publicado: (2021)

Clinical and genetic factors associated with radiographic damage in patients with ankylosing spondylitis
por: Nam, Bora, et al.
Publicado: (2023)

Evidence for a second ankylosing spondylitis-associated RUNX3 regulatory polymorphism
por: Vecellio, Matteo, et al.
Publicado: (2018)

Changes in ankylosing spondylitis incidence, prevalence and time to diagnosis over two decades
por: Crossfield, Samantha S R, et al.
Publicado: (2021)

Functional Genomic Analysis of a RUNX3 Polymorphism Associated With Ankylosing Spondylitis
por: Vecellio, Matteo, et al.
Publicado: (2021)

Fifty years after the discovery of the association of HLA B27 with ankylosing spondylitis
por: Braun, Juergen, et al.
Publicado: (2023)

Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2
por: Marzo-Ortega, Helena, et al.
Publicado: (2017)

Intestinal microbiota changes induced by TNF-inhibitors in IBD-related spondyloarthritis
por: Ditto, Maria Chiara, et al.
Publicado: (2021)

Ankylosing spondylitis and mortality following hospitalised pneumonia: a population-based cohort study
por: Holland-Fischer, Mette, et al.
Publicado: (2020)

Incidence of extra-articular manifestations in ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis: results from a national register-based cohort study
por: Bengtsson, Karin, et al.
Publicado: (2020)

Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration
por: Michelsen, Brigitte, et al.
Publicado: (2020)

Social Role Participation Questionnaire for patients with ankylosing spondylitis: translation into Dutch, reliability and construct validity
por: van Genderen, Simon, et al.
Publicado: (2016)

Trends in treatment and outcomes of ankylosing spondylitis in outpatient rheumatological care in Germany between 2000 and 2012
por: Huscher, Dörte, et al.
Publicado: (2015)

Non-classical human leucocyte antigens in ankylosing spondylitis: possible association with HLA-E and HLA-F
por: Santos, Margarida Rodrigues, et al.
Publicado: (2018)

Relationship between the gut and the spine: a pilot study of first-degree relatives of patients with ankylosing spondylitis
por: Kehl, Amy S, et al.
Publicado: (2017)

Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study
por: Deodhar, Atul, et al.
Publicado: (2021)

Characterisation of gut microbiota composition in patients with axial spondyloarthritis and its modulation by TNF inhibitor treatment
por: Vallier, Marie, et al.
Publicado: (2023)

Long-term efficiency of infliximab in patients with ankylosing spondylitis: real life data confirm the potential for dose reduction
por: Baraliakos, X, et al.
Publicado: (2016)

Immune response profiling of patients with spondyloarthritis reveals signalling networks mediating TNF-blocker function in vivo
por: Menegatti, Silvia, et al.
Publicado: (2021)

Lifestyle factors may modify the effect of disease activity on radiographic progression in patients with ankylosing spondylitis: a longitudinal analysis
por: Ramiro, Sofia, et al.
Publicado: (2015)

Employment and the role of personal factors among patients with ankylosing spondylitis: a Dutch cross-sectional case-control study
por: Webers, Casper, et al.
Publicado: (2018)

Cardiac conduction disturbances in patients with ankylosing spondylitis: results from a 5-year follow-up cohort study
por: Bengtsson, Karin, et al.
Publicado: (2019)

Difficult-to-treat axial spondyloarthritis is associated with psoriasis, peripheral involvement and comorbidities: results of an observational nationwide study
por: Fakih, Olivier, et al.
Publicado: (2023)

Effect of Secukinumab on Patient‐Reported Outcomes in Patients With Active Ankylosing Spondylitis: A Phase III Randomized Trial (MEASURE 1)
por: Deodhar, Atul A., et al.
Publicado: (2016)

Effect of upadacitinib on reducing pain in patients with active psoriatic arthritis or ankylosing spondylitis: post hoc analysis of three randomised clinical trials
por: McInnes, Iain B, et al.
Publicado: (2022)

Characterising the axial phenotype of psoriatic arthritis: a study comparing axial psoriatic arthritis and ankylosing spondylitis with psoriasis from the REGISPONSER registry
por: Michelena, Xabier, et al.
Publicado: (2022)

Factors associated with the retention of secukinumab in patients with axial spondyloarthritis in real-world practice: results from a retrospective study (FORSYA)
por: Dougados, Maxime, et al.
Publicado: (2023)

Secukinumab and Sustained Improvement in Signs and Symptoms of Patients With Active Ankylosing Spondylitis Through Two Years: Results From a Phase III Study
por: Marzo‐Ortega, H., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_7iet64kkg3cufsk6ptqr7remq5